



J. Lamarck Pharma - Class A

March 2025

LU1224032034

<https://www.tmf-group.com>

UCITS SICAV

INVESTMENT STRATEGY

The main objective of SELECTRA Investments Sicav – J. Lamarck Pharma is to profit from a rise in stock prices in the pharmaceutical industry worldwide. The model portfolio consists of mature pharmaceutical corporations and innovative companies with pipelines of products in development in one or several markets. The investment policy will allow the fund to increase total return through an active stock selection of companies that offer the most promising technology platforms.

CUMULATIVE FUND PERFORMANCE

	Fund
1 month	-6.27%
3 months	-2.00%
6 months	-5.15%
12 months	-5.19%
YTD *	-2.00%

MARKET PERFORMANCE

Markets	1 Month
DAX	-1.72%
EURO STOXX 50	-3.94%
FTSE MIB	-1.56%
DOW JONES INDUSTRIAL	-4.20%


TOP HOLDINGS

Asset	Market Value (EUR)	% AUM
Fresenius SE & Co KGaA	354,330.00	5.59
Valneva SE	348,944.00	5.50
Taro Pharm Industries Ltd A	302,522.56	4.77
Organon & Co	290,839.16	4.59
Teva Pharma Ind Ltd ADR repr 1 Share	290,255.03	4.58

FUND DATA

NAV Class A (31.03.2025)	EUR 111.98
AUM	EUR 6.34 Mio
Launch date	30 th June 2015
Domiciliation	2 Rue d'Alsace, L-1122 Luxembourg
R.C.S.	Luxembourg, B136880
Investment Advisor	J. Lamarck S.p.A.
Auditor	Deloitte Audit S.à r.l.
Depository Bank	Quintet Private Bank (Europe) S.A.
Contact	TMF Fund Management S.A. 46A, Avenue John F. Kennedy L-1855 Luxembourg Tel: +352 42 71 71 1 info.fundmanagement@tmf-group.com

COUNTRY ALLOCATION



FUND PERFORMANCE



INVESTMENT TERMS

	Class A	Class B	Class D
Advisory Fee	up to 0.8% p.a.	up to 1.3% p.a.	up to 1.3% p.a.
Minimum amount invested	EUR 1,000,000	EUR 5,000	1 share
Performance Fee	10% p.a. with HWM**	10% p.a. with HWM**	10% p.a. with HWM**
Bloomberg ticker	SELJLPA LX	SELJLPB LX	SELJLP IM
ISIN	LU1224032034	LU1224032463	LU1246176850

* Since 31 December 2024

** High Water Mark

For more details regarding the investment in this Fund, including potential risks, please refer to the current Full or Simplified Prospectus (the "Prospectus") available at SIS's offices.

This Fund is a sub-fund of the Luxembourg-registered Selectra Investments SICAV ("SIS"). This document has been prepared solely for information purposes and shall not be considered as an advice or solicitation to invest in SIS. Shares in SIS will only be issued and distributed on the basis of the Prospectus. The strategy employed may result in the Net Asset Value of the Fund exhibiting a high level of volatility and SIS is only suitable for investors in a position to take such risks. The value of investments may go down as well up and you may not get back your original investment. Changes in rate of exchange between currencies may cause the value of investments to decrease or increase. No liability whatsoever is accepted by SIS for any loss howsoever arising from any use of this report or its contents.